▲ +60.19% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BioVie in the last 3 months. The average price target is $47.00, with a high forecast of $47.00 and a low forecast of $47.00. The average price target represents a 60.19% upside from the last price of $29.34.
The current consensus among 1 contributing investment analysts is to buy stock in BioVie.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.